COSCIENS Biopharma Inc
CSCI2.720USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
8.64MMarket Cap
LossP/E TTM
More Details of COSCIENS Biopharma Inc Company
COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.
COSCIENS Biopharma Inc Info
Ticker SymbolCSCI
Company nameCOSCIENS Biopharma Inc
IPO dateDec 19, 1995
CEOMs. Anna Biehn
Number of employees- -
Security typeOrdinary Share
Fiscal year-endDec 19
AddressC/O Norton Rose Fulbright Canada Llp
CityTORONTO
Stock exchangeThe Toronto Stock Exchange
CountryCanada
Postal codeM5K 1E7
Phone18439003201
Websitehttps://www.cosciensbio.com/
Ticker SymbolCSCI
IPO dateDec 19, 1995
CEOMs. Anna Biehn
Company Executives of COSCIENS Biopharma Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Mr. Ronald W. (Ronnie) Miller
Mr. Ronald W. (Ronnie) Miller
Director
Director
--
--
Mr. Peter H. Puccetti
Mr. Peter H. Puccetti
Chairman of the Board, Interim Chief Executive Officer
Chairman of the Board, Interim Chief Executive Officer
--
--
Mr. David Spear
Mr. David Spear
Director
Director
--
--
Mr. Anthony J. Giovinazzo
Mr. Anthony J. Giovinazzo
Director
Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Ulrich Kosciessa
Dr. Ulrich Kosciessa
Director
Director
1.85K
--
Mr. Robert A. Seager
Mr. Robert A. Seager
Director
Director
--
--
Ms. Nicola Ammer
Ms. Nicola Ammer
Senior Vice President - Clinical Development, Chief Medical Officer
Senior Vice President - Clinical Development, Chief Medical Officer
--
--
Dr. Matthias Gerlach
Dr. Matthias Gerlach
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
Senior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany
--
--
Mr. Giuliano La Fratta
Mr. Giuliano La Fratta
Chief Financial Officer, Senior Vice President
Chief Financial Officer, Senior Vice President
--
--
Mr. Michel Regnier
Mr. Michel Regnier
Senior Vice President, Chief Technology Officer
Senior Vice President, Chief Technology Officer
--
--
Revenue Breakdown
Currency: USDUpdated: Sun, Apr 6
Currency: USDUpdated: Sun, Apr 6
FY2023
FY2022
FY2021
FY2020
FY2019
FY2018
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
Switzerland
4.32M
95.98%
Ireland
122.00K
2.71%
Other
48.00K
1.07%
Denmark
11.00K
0.24%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Sun, Nov 16
Updated: Sun, Nov 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
TD Waterhouse Canada, Inc.
0.12%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Other
90.35%
Shareholders
Shareholders
Proportion
Goodwood Inc.
8.08%
Gagnon (Gilles R)
1.32%
TD Waterhouse Canada, Inc.
0.12%
Li (William W. M.D.)
0.08%
Kosciessa (Ulrich)
0.06%
Other
90.35%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
8.08%
Individual Investor
1.48%
Investment Advisor
0.12%
Other
90.32%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
32
283.56K
8.74%
-15.54K
2025Q2
37
331.27K
10.53%
-6.89K
2025Q1
40
333.44K
10.61%
+29.17K
2024Q4
39
327.35K
8.67%
+13.77K
2024Q3
37
287.99K
7.73%
+16.16K
2024Q2
43
256.95K
8.09%
+189.65K
2024Q1
39
61.15K
4.98%
+40.02K
2023Q4
42
13.03K
1.07%
-9.47K
2023Q3
49
18.14K
1.49%
-6.74K
2023Q2
52
14.44K
1.19%
-13.85K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Goodwood Inc.
257.26K
8.1%
--
--
Jun 03, 2025
Gagnon (Gilles R)
41.96K
1.32%
--
--
Mar 26, 2025
TD Waterhouse Canada, Inc.
3.86K
0.12%
+143.00
+3.85%
Jun 30, 2025
Li (William W. M.D.)
2.40K
0.08%
--
--
Mar 26, 2025
Kosciessa (Ulrich)
1.85K
0.06%
--
--
Jun 03, 2025
Prefontaine (Stacy)
767.00
0.02%
+767.00
--
Jun 03, 2024
Osaic Holdings, Inc.
50.00
0%
--
--
Jun 30, 2025
Planning Capital Management Corp
2.00
0%
--
--
Sep 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Date
Type
Ratio
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
May 01, 2024
Merger
4→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
Jul 19, 2022
Merger
25→1
FAQs
Who are the top five shareholders of COSCIENS Biopharma Inc?
The top five shareholders of COSCIENS Biopharma Inc are:
Goodwood Inc. holds 257.26K shares, accounting for 8.10% of the total shares.
Gagnon (Gilles R) holds 41.96K shares, accounting for 1.32% of the total shares.
TD Waterhouse Canada, Inc. holds 3.86K shares, accounting for 0.12% of the total shares.
Li (William W. M.D.) holds 2.40K shares, accounting for 0.08% of the total shares.
Kosciessa (Ulrich) holds 1.85K shares, accounting for 0.06% of the total shares.
Goodwood Inc. holds 257.26K shares, accounting for 8.10% of the total shares.
Gagnon (Gilles R) holds 41.96K shares, accounting for 1.32% of the total shares.
TD Waterhouse Canada, Inc. holds 3.86K shares, accounting for 0.12% of the total shares.
Li (William W. M.D.) holds 2.40K shares, accounting for 0.08% of the total shares.
Kosciessa (Ulrich) holds 1.85K shares, accounting for 0.06% of the total shares.
What are the top three shareholder types of COSCIENS Biopharma Inc?
The top three shareholder types of COSCIENS Biopharma Inc are:
Goodwood Inc.
Gagnon (Gilles R)
TD Waterhouse Canada, Inc.
Goodwood Inc.
Gagnon (Gilles R)
TD Waterhouse Canada, Inc.
How many institutions hold shares of COSCIENS Biopharma Inc (CSCI)?
As of 2025Q3, 32 institutions hold shares of COSCIENS Biopharma Inc, with a combined market value of approximately 283.56K, accounting for 8.74% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -1.79%.
What is the biggest source of revenue for COSCIENS Biopharma Inc?
In FY2023, the -- business generated the highest revenue for COSCIENS Biopharma Inc, amounting to -- and accounting for --% of total revenue.
